Referential content
Treasurer’s report
The 2024 financial year has been pivotal with changes in personnel, increased member engagement, and further development of the in-house research and trial coordination resources of the organisation.
In the 2024 financial year, AGITG invested $16,692,908 on scientific trials, with $1,853,273 generously donated from our dedicated GI cancer community. In total over the past 34 years, AGITG has supported research with over $110 million to improve outcomes for patients with GI cancer.
The financial management of the AGITG continues to have scientific research and member engagement as its focus, noting that many components are necessary, including governance, funding support, communication, quality and compliance measures, and industry engagement.
The Board and the management team of the AGITG are aligned in balancing all these factors with recognition of the demands of today and the future.
I wish to acknowledge the contributions of the late Russell Conley for the legacy he has provided to the financial disciplines of the AGITG and thank Joanne Cory for her leadership of the AGITG during a period of significant change.
Treasurer
BBus (Marketing), SIA Diploma of Finance
Year at a glance
January
- Our FORECAST-1 study was published in Cell Reports Medicine.
- We welcomed Ebony Gaylor to our Board.
- DYNAMIC-Rectal and NABNEC abstracts were presented at ASCO Gastrointestinal Cancers Symposium in the Rapid Oral Abstract session.
February
- Professor Tim Price stepped down from our Board of Directors.
- We welcomed Dr John Mak, Medical Oncologist, to the team as our newly appointed Clinical Research Fellow.
- The annual Alex and Adam Golf Day hosted by John Paduano in Mollymook, raised $12,000 for GI cancer research.
March
- Grampians Gutsy Challenge trek led by Professor Rob Ramsay. Together the team raised $31,000.
- We welcomed Bridget Rooney to the team as the Clinical Development Coordinator working closely with Louise Christophersen, our Clinical Development Lead.
April
- We announced our Paid Parental Leave Policy.
- We welcomed Amy Bruce to the Research Team as the Clinical Trial Quality Specialist.
- Patient recruitment target of 460 was reached for the INTEGRATE IIb clinical trial for stomach and oesophageal cancer.
- Kealan Harkin raised over $4,000 in The Canberra Marathon Festival, which he ran in memory of his father, who sadly passed away from GI cancer in 2023.
May
- International recruitment for ACTICCA-1 was completed.
- Melanie, our Fundraising Lead, gave birth to a beautiful baby boy.
- We welcomed three new team members: Mel’s parental leave cover Tiffany Meiliunas, Miriam Roesner as the new Clinical Operations Lead, and Breeda Monaghan into the new role of Finance Manager.
- We held our seventh Idea Generation Workshop, this time focused on anal cancer.
- Community fundraiser, Coeus Advisors, raised more than $45,000 for Colorectal Cancer Research.
- Nisha Berthon-Jones, Head of Research Operations, presented at the Australian Comprehensive Cancer Network Innovations Showcase where she detailed AGITG’s journey toward equitable cancer care in clinical trials and how we embed equity in all aspects of our work.
- Our Clinical Program Manager, Sandra Bahamad, and our Clinical Development Lead, Louise Christophersen, presented at Regional Clinical trials Coordinating Centre (RCCC) where they presented on AGITG Teletrial Advocacy and Implementation.
- Professor Niall Tebbutt retired from the Board of Directors.
June
- Our clinical trials DYNAMIC-Pancreas, MONARCC and NEO-CREATE featured at the world-leading cancer research meeting ASCO, drawing the attention of clinicians from all over the globe.
- Louise Christophersen attended ASCO this year, organising industry and collegiate meetings.
- Our first trial fully funded by the community, NEO-IMPACT, completed recruitment.
- We welcomed Ingrid Laycock, our new Clinical Project Coordinator, who joined our newly opened Clinical Research Centre team.
- Denise Lindsell and Brooke Smeekens Coleman raised over $117,000 at the Kununurra Black Tie Fundraiser in WA, more than $60,000 of which was donated to GI Cancer Institute.
July
- Milton Kirkwood retired from the Community Advisory Panel after four years, including one year as Deputy Chair.
- We welcomed Megan Pope to the team as our new Direct Marketing Lead.
August
- Lis Boyce from Piper Alderman ran City2Surf and raised over $4,000.
- Dr Sarah Tregenza and a team of 16 colleagues from Pierre Fabre ran the City2Surf in Sydney and raised close to $1,600.
- Blake Creighton held the ‘Putt for Kaz’ Golf Day in memory of his mother who passed away from stomach cancer. The event raised over $20,000.
- Jodie Collins was unanimously appointed to the role of Deputy Chair for the Community Advisory Panel.
- We welcomed Stephen Deed, Brooklynn Dowling, John Paduano and Margaret Whitson to the Community Advisory Panel.
- A translational substudy of our oesophageal cancer trial DOCTOR was published in Genome Medicine.
- The BIOMARCER-2 colorectal cancer trial opened to recruitment.
September
- We welcomed Ali Bramson as the new Philanthropy and Fundraising Manager for the fundraising team.
- The first trial coordinated by the AGITG Clinical Research Centre, STOPNET, opened to patient recruitment.
- The Blue Mountains Gutsy Challenge, led by Professor Haryana Dhillon and joined by 11 trek participants, raised close to $20,000.
- Jackie Green raised close to $3,000 from her heavy metal benefit concert in honour of her husband David, who passed away from oesophageal cancer.
- Alison Garnet held her second Golf Day and raised $8,000 for GIST.
- AGITG TOPGEAR clinical trial findings were published in the New England Journal of Medicine and presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain by Study Chair Professor Trevor Leong.
- AGITG were the selected beneficiary of a donation from Lachlan Kean Foundation (LKF), a bridging foundation started by a group of friends in honour of Lachlan Kean who passed away from bowel cancer. Nisha Berthon-Jones was invited to attend the LKF Gala Dinner to accept the donation.
- We farewelled Russell Conley as CEO, who retired after 22 dedicated years of service and exemplary leadership.
- Kylie Barton, on behalf of Pfeiffer Wines, held their annual ‘Crazy Dave Wine Sale’ in honour of colleague and friend Dave Willis. The wine sale raised $4,000.
October
- Joanne Cory was appointed as the new CEO of AGITG.
- Our stomach cancer and oesophageal cancer study INTEGRATE IIa was published in Journal of Clinical Oncology.
- We were incredibly proud to announce the opening of the new, world-first cholangiocarcinoma trial, BIL-PPP.
November
- Riversdale Golf Club held their second golf day in support of new pancreatic cancer research, raising $11,500.
- Vince Colagiuri held the Dominic Colagiuri Memorial Cup in November, raising close to $3,000 for colorectal cancer.
- The community at the Mike Leeke Golf Day raised $5,500 for bowel cancer research in memory of their sport-loving friend Mike Leeke, who sadly passed from bowel cancer in 2018.
- Our 26th Annual Scientific Meeting was held in Meeanjin / Brisbane, themed ‘Thinking Outside the Box’.
- A First Nations-led video series, directed by Madison Shakespeare, Gadigal Traditional Custodian and former AGITG Community Advisory Panel Member, was created and will launch in 2025.
- It was with great sadness that we shared the news of Russell Conley's passing, a loss deeply felt across our team, membership and community.
December
- We were awarded a $100,000 grant for the REGATTA colorectal cancer clinical trial and a $200,000 grant for the BIL-PPP cholangiocarcinoma clinical trial from Tour de Cure Australia!
- We received an incredibly generous donation of $150,000 from Alcheringa who represents the Mount Burdett Foundation in WA.
Grants
Infrastructure grants
Cancer Australia provides funding through the ‘Support for Cancer Clinical Trials’ program, with the primary aim to support the AGITG in developing industry-independent cancer clinical trials.
Funding
Cancer Australia funding is for three years from 1 July 2024 to 30 June 2027. The grant provides the AGITG with up to $1,585,145 in infrastructure funding over the grant period.
Research grants
Funds provided by Cancer Australia, Cancer Council, the National Health & Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF) in support of trial coordination may be managed through third-party Administering Institutions including the University of Sydney NHMRC Clinical Trials Centre and the Walter and Eliza Hall Institute (WEHI), in addition to AGITG. Funds managed by third parties are transferred to the AGITG to support site payments and insurance costs relating to these studies and are reflected as such in these financial accounts.
Grants supporting trials conducted during the 2024 financial year are outlined below. AGITG grant income and expenditure during the 2024 year for these trials are included in the 2024 Income Statement.
ACTICCA-1
A multi-centre, prospective, randomised, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs. observation alone in patients after curative intent resection of Biliary Tract Cancer (BTC).
Funding
- Cancer Australia Grant: $163,600 (2016)
ASCOLT
An international randomised, double blind, placebo controlled phase III multi-centre trial, investigating the effect of aspirin on disease free and overall survival as adjuvant treatment in patients with resected stage II and III colorectal cancer.
Funding
- Cancer Australia and Bowel Cancer Australia Grant: $328,000 (2014)
- Cancer Australia Grant: $465,000 (2019)
BIL-PPP
Open-label, single-arm, signal-seeking phase II study of the combination of durvalumab and olaparib in advanced cholangiocarcinoma after initial chemotherapy and durvalumab.
Funding
- Tour de Cure Senior Research Grant: $200,000 (2024)
CONTROL NETS
Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study.
Funding
- NeuroEndocrine Cancer Australia (formerly Unicorn Foundation): $200,000 (2015), $105,000 (2017) and $200,000 (2019)
- University of Sydney Bridging Grant: $30,000 (2015)
DYNAMIC-Rectal
This initial study has been designed to determine whether a ctDNA-based approach to adjuvant therapy will lead to substantially less patients receiving adjuvant therapy.
Funding – Walter and Eliza Hall Institute
- NHMRC Project Grant $1,316,682 (2017)
MASTERPLAN
This study aims to determine if adding stereotactic body radiotherapy (SBRT) to modern chemotherapy (mFOLFIRINOX or gemcitabine/nab-paclitaxel) for patients with high-risk or unresectable (also called locally advanced) pancreatic cancer improves cancer control rates in and around the pancreas.
Funding – University of Sydney NHMRC Clinical Trials Centre
- Medical Research Future Fund: $1,512,808 (2018)
NABNEC
A Randomised Phase II Study of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment of Gastrointestinal Neuroendocrine Carcinomas.
Funding – University of Sydney NHMRC Clinical Trials Centre
- NHMRC Project Grant: $360,750 (2016)
PemOla
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden ≥ 4mutations/Mb.
Funding
- PanKind Research Grant: $297,548 (2024)
- Tour de Cure Matching Grant: $50,000 (2024)
- Epworth Medical Foundation Research Grant: $30,550 (2024)
REGATTA
A phase II randomised placebo‐controlled study testing regorafenib with capecitabine and aspirin or placebo in refractory metastatic colorectal cancer.
Funding
- Tour de Cure Matching Grant: $100,000 (2024)
RESOLUTE
Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
Funding – Walter and Eliza Hall Institute
- Cancer Council Victoria Grant: $299,548 (2021)
SPAR
Simvastatin with chemotherapy and radiation in preoperative treatment for rectal cancer: a randomized, placebo-controlled phase 2 trial.
Funding
- Cancer Society of New Zealand Grant: $149,290 NZD (2015)
- Cancer Council NSW Grant: $449,448 AUD (2016)
- Cancer Australia Grant: $148,857 AUD (2017)
SSGXXII
Three or five years of adjuvant imatinib for the treatment of patients with operable GIST with a high risk of relapse: A randomized phase III study.
Funding – University of Sydney NHMRC Clinical Trials Centre
- Medical Research Future Fund: $1,036,125 (2021)
STOPNET
Comparison of patient outcomes with or without continuation of somatostatin injections after the commencement of Peptide Receptor Radionuclide Therapy (PRRT)
Funding
- Tour de Cure Grant 2022: $50,000 (2023)
- Medical Research Future Fund Clinical Trial Activity Grant 2023: $1,285,405 (2024)
TOPGEAR
A randomised phase II/III trial of pre-operative chemoradiotherapy versus pre-operative chemotherapy for resectable gastric cancer.
Funding
- NHMRC Grant: $756,136 (2013)
- NHMRC Grant: $621,644 (2021)
Our publications and presentations
Publications
- CommNETs study
Loree JM, Chan D, Lim J, et al. Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs. JAMA Oncol. Published online October 03, 2024. doi:10.1001/jamaoncol.2024.4330 - DOCTOR study
Sandra Brosda, Lauren G. Aoude, Vanessa F. Bonazzi, Kalpana Patel, James M. Lonie, Clemence Belle, Lambros T. Koufariotis, Venkateswar Addala, Felicity Newell, Marjan M. Naeini, AGITG DOCTOR Investigators, Lutz Krause, Nicola Waddell, Andrew P. Barbour. Heterogeneity in Oesophageal Adenocarcinoma – a multi-region and multi-timepoint study. Genome Med 16, 90 (2024). https://doi.org/10.1186/s13073-024-01362-z - GENESCREEN 5-FU study
White C, Wardill H, Paul C, Price T, Karapetis C, Nalder M, Burge ME, Thomas A, Oldmeadow C, Barker D, Edney LC, Coller J, Bowen J, Ostroff C, Cheek B, Carlson M, Rankmore T, Nagrial A, Clarke S, Chantrill L, Ackland S, Scott RJ. DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. BMC Cancer. 2024 Nov 8;24(1):1369. doi: 10.1186/s12885-024-13122-8. PMID: 39516829; PMCID: PMC11549825. - INTEGRATE IIa study
Nick Pavlakis, Kohei Shitara, Katrin Sjoquist, Andrew Martin, Anthony Jaworski, Niall Tebbutt, Yung-Jue Bang, Thierry Alcindor, Chris O’Callaghan, Andrew Strickland, Sun Young Rha, Keun-Wook Lee, Jin-Soo Kimm, Li-Yuan Bai, Hikori Hara, Do-Youn Oh, Sonia Yip, John Zalcberg, Tim Price, John Simes, David Goldstein. Regorafenib for the treatment of advanced gastric and gastro-oesophageal junction cancer (AGOC): Final results from the AGITG INTEGRATE IIa study, a Phase 3 Randomised double-blind study of regorafenib versus placebo in refractory advanced AGOC. J Clin Oncol. 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055. Epub ahead of print. PMID: 39365958. - MONARCC study
Matthew E. Burge, David Espinoza, Katrin Marie Sjoquist, Derrick HW Sui, Rebecca Mercieca-Bebber, Lorraine A. Chantrill, Christos Stelios Karapetis, Christopher B. Steer, Sonia Yip, Jeff Cuff, Stephanie Winata, Jeanne Tie, Darshit Arunbhai Thaker, Ratnesh Srivastav, Ehtesham Abdi, Andrew Strickland, Eva Segelov, Alessandra Francesconi, Timothy Price, Rahul Ladwa, Warren Joubert, Niall C. Tebbutt. AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab plus 5-Fluorouracil as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer. A study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clin Colorectal Cancer. 2024 Dec 12:S1533-0028(24)00112-9. doi: 10.1016/j.clcc.2024.11.003. Epub ahead of print. PMID: 39779412. - PALEO study
Fiona Day, Swetha Sridharan, Catherine Johnson, Gaik T Quah, Girish Mallesara, Mahesh Kumar, Amber-Louise Poulter, Anthony Morrison, Allison Fraser, Christopher Oldmeadow, Jarad Martin. Oesophageal chemoradioimmunotherapy: A pilot study in the palliative management of oligometastatic disease. Asia-Pac J Clin Oncol. 2024;1–7. Published online: 21 March 2024. - SOCRATES HCC study
Wigg A, Tibballs J, Woodman R, Stuart K, Le H, Roberts SK, Olynyk JK, Strasser SI, Wallace M, Martin J, Haworth A, Hardcastle N, Loo KF, Tang C, Lee YY, Chu J, De Abreu Lourenco R, Koukourou A, De Boo D, McLean K, Buck J, Sawhney R, Nicoll A, Dev A, Wood M, Braund A, Weltman M, Khor R, Levy M, Wang T, Potter M, Haridy J, Raj A, Duncan O, Zekry A, Collier N, O'Beirne J, Holliday C, Trada Y, Tronidjaja J, George J, Pryor D. A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC). BMC Cancer. 2024 Jul 8;24(1):813. doi: 10.1186/s12885-024-12504-2. PMID: 38973009; PMCID: PMC11229272. - TOPGEAR study
Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, O'Connell RL, Zalcberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O'Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J; Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group. Preoperative Chemoradiotherapy for Resectable Gastric Cancer. N Engl J Med. 2024 Sep 14. doi: 10.1056/NEJMoa2405195. Epub ahead of print. PMID: 39282905.
Presentations
- ACME ABC study
McKay, Owen, Lundy Joanne, Perry, Andrew, Wilson, Trevor J, Croagh, Daniel. The Australian Comprehensive Molecular Evaluation Of Advanced Biliary Cancer Trial (ACME ABC) – EUS Biopsies And Cholangioscopic Biopsies For Molecular Analysis. Interim Results. Digestive Disease Week (May 2024) - oral presentation. - CORONET study
David Chan, Mark Doherty, Simron Singh, Michael Michael, Grace Kong, David Ransom, David Wyld, Tim Price, Gabby Cehic, Ben Lawrence, Paul Roach, Nick Pavlakis. CAPTEM and PRRT to improve Overall Response for pancreatic NETs (pNETs) – the CORONET trial. ENETs conference (March 2024) - poster presentation. - DYNAMIC-Pancreas study
Belinda Lee, Jeanne Tie, Yuxuan Wang, Joshua D. Cohen, Jeremy David Shapiro, Rachel Wong, Morteza Aghmesheh, Andrew Ddembe Kiberu, Alessandra Francesconi, Matthew E. Burge, Amitesh Chandra Roy, Lisa Dobbyn, Janine Ptak, Natalie Silliman, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Peter Gibbs. The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial. ASCO (May/June 2024) - oral presentation. - DYNAMIC-Rectal study
Jeanne Tie, Joshua D Cohen, Yuxuan Wang, Pablo Matias Gonzalez Ginestet, Rachel Wong, Jeremy Shapiro, Rob Campbell, Fiona Day, Theresa Hayes, Morteza Aghmesheh, Chris Karapetis, Maria Popoli, Lisa Dobbyn, Janine Ptak, Natalie Silliman, Christopher Douville, Nicholas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, Peter Gibbs. Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: The Randomized AGITG DYNAMIC-Rectal Study. ASCO GI (Feb 2024) - rapid oral presentation. - FORECAST-1 study
Tao Tan, Dmitri Mouradov, Margaret Lee, Grace Gard, Yumiko Hirokawa, Shan Li, Cong Lin, Fuqiang Li, Huijuan Luo, Kui Wu, Michelle Palmieri, Evelyn Leong, Jordan Clarke, Anuratha Sakthianandeswaren, Helen Brasier, Jeanne Tie, Niall C. Tebbutt, Azim Jalali, Rachel Wong, Antony W. Burgess, Peter Gibbs, and Oliver M. Sieber. Unified Framework for Personalizing Colorectal Cancer Treatment Using Tumor Organoids in Suspension Culture. Biomolecular Horizons 2024 (September 2024) - poster presentation. - FORECAST-1 study
Tao Tan, Dmitri Mouradov, Margaret Lee, Grace Gard, Yumiko Hirokawa, Shan Li, Cong Lin, Fuqiang Li, Huijuan Luo, Kui Wu, Michelle Palmieri, Evelyn Leong, Jordan Clarke, Anuratha Sakthianandeswaren, Helen Brasier, Jeanne Tie, Niall C. Tebbutt, Azim Jalali, Rachel Wong, Antony W. Burgess, Peter Gibbs, and Oliver M. Sieber. Unified Framework for Personalizing Colorectal Cancer Treatment Using Tumor Organoids in Suspension Culture. Cell Symposia: Engineering development and disease in organoids (August 2024) - poster presentation. - MONARCC study
Matthew E. Burge, David Espinoza, Katrin Marie Sjoquist, Derrick HW Siu, Rebecca Mercieca-Bebber, Lorraine A. Chantrill, Christos Stelios Karapetis, Christopher B. Steer, Sonia Yip, Jeff Cuff, Stephanie Winata, Jeanne Tie, Darshit Arunbhai Thaker, Niall C. Tebbutt. AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG). ASCO (May/June 2024) - poster presentation. - NABNEC study
Lorraine A. Chantrill, David Ransom, David Chan, Adnan Nagrial, Nick Pavlakis, Ben Markman,Christos Stelios Karapetis, Katrin Marie Sjoquist, John Simes, Val Gebski, Michael S Hofman,Pablo Gonzalez Ginestet, Anthony J. Gill, Sonia Yip, Michael Michael, Anthony Jaworski, Ho Wai Derrick Siu, Mustafa Khasraw. NABNEC - A Randomised Phase II Study Of nab-paclitaxel In Combination with Carboplatin As First Line Treatment of Gastrointestinal Neuroendocrine Carcinomas (GI-NECs). ASCO GI (Feb 2024) - rapid oral presentation. - NEO-CREATE study
Amitesh Chandra Roy, Tim F Bright, Nimit Singhal, Matthew E. Burge, Eva Segelov, Andrew Mark Haydon, Lorraine A. Chantrill, Michael Michael, Caroline Connell, David Moffat, Richard John Woodman, Michael Michael, Erin Symonds, Timothy Jay Price, Alex Scott-Hoy, Alison Richards, Christos Stelios Karapetis. Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial. ASCO (May/June 2024) - poster presentation. - OMEGCA study
Zexi Allan, Yuxuan Wang, Jeanne Tie, Niall Tebbutt, Nicholas Clemons, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, David S. Liu. Peritoneal tumor DNA as a prognostic biomarker in locally advanced gastroesophageal cancer: A pilot prospective cohort study. AANZGOSA ASM (November 2024) - accepted as an oral presentation. - OMEGCA study
Zexi Allan, Yuxuan Wang, Jeanne Tie, Niall Tebbutt, Nicholas Clemons, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, David S. Liu. Peritoneal tumor DNA as a prognostic biomarker in locally advanced gastroesophageal cancer: A pilot prospective cohort study. AACR Liquid Biopsy (November 2024) - accepted as a poster presentation. - TOPGEAR study
Trevor Leong, B. Mark Smithers, Michael Michael, Karin Haustermans, Rebecca Wong, Val Gebski, Rachel L O’Connell, John Zalcberg, Alex Boussioutas, Michael Findlay, David Willis, Alisha Moore, Florian Lordick, Chris O’Callaghan, Carol Swallow, Gail Darling, Andrew Strickland, Moishe Liberman, Laurent Mineur, John Simes. A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG. ESMO (September 2024) - oral presentation, proferred paper session (GI Cancer, upper GI).